GeneDx to Showcase Scale of Infinity Dataset at ACMG 2026 with 18 Abstracts
Event summary
- GeneDx will present 18 abstracts at the ACMG 2026 Annual Meeting, including three platform presentations and two rapid-fire poster talks.
- Research spans sequencing innovations, AI-supported interpretation, novel gene-disease discoveries, and real-world impact of earlier diagnoses.
- Data highlights the scale of GeneDx Infinity™, with over a million exomes and genomes linked to deep clinical context.
- AI-powered MIMI Ranker demonstrated high recall of pathogenic variants while significantly reducing manual interpretation time.
The big picture
GeneDx's presentation at ACMG 2026 underscores its leadership in rare disease diagnosis through the scale and clinical impact of its GeneDx Infinity™ dataset. The company is leveraging AI and advanced sequencing methods to enhance variant interpretation and accelerate analysis, positioning itself as a key player in the shift towards genomic precision medicine. Strategic collaborations with partners like Illumina and SeqFirst further solidify its role in driving exome and genome sequencing toward standard care.
What we're watching
- AI Integration
- How GeneDx's AI-powered tools will affect the speed and accuracy of rare disease diagnosis.
- Market Expansion
- Whether GeneDx can sustain its leadership in bringing exome and genome testing to standard care across diverse clinical settings.
- Regulatory Landscape
- The pace at which regulatory approvals will enable broader adoption of genomic testing technologies.
Related topics